Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $226 from $225 and keeps an Overweight rating on the shares. The firm updated estimates following the company’s Q4 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $255 from $210 at Deutsche Bank
- Jazz Pharmaceuticals price target raised to $275 from $263 at BofA
- Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo
- Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
- Jazz Pharmaceuticals reports Q4 adjusted EPS $6.64 vs. $6.51 last year